Glenmark Pharmaceuticals ltd — Capital/Financing Update 2018

Sep 25, 2018

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

September 25, 2018

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296 Ref: Scrip Name: GLENMARK Dear Sirs,

Re: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure

Requirements) Regulations, 2015 to consider repurchase of Foreign Currency Debt

• A. We hereby inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, a meeting of the Board of Directors of Glenmark Pharmaceuticals Limited (“ Company ”) will be held on September 28, 2018, to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million 2 per cent resettable onward starting equity linked securities due June 28, 2022 issued in 2016 (“ FCC Bonds ”) and / or, its U.S.$200 million 4.5% senior notes due 2021 issued in 2016 (“ FCY Bonds ”), based on market opportunities and conditions from time to time and to delegate powers to operations committee. The Operations Committee, based on market opportunities and conditions, will hold meetings during the next one month to consider and approve the terms and conditions of any tenders or buybacks.

• B. This is for the information of your members and all concerned in compliance with the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended.

The above is for your information.

Thanking you

Yours faithfully, For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK KUBER VINAYAK KUBER Date: 2018.09.25 15:43:26 +05'30' Harish Kuber

Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879 Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com